Alzheimer disease (AD) is the most common form of neurodegenerative disease, estimated
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Background Biomarker changes that occur in the period between normal cognition and the
diagnosis of sporadic Alzheimer's disease have not been extensively investigated in …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

Several attempts have been made to treat Alzheimer's disease (AD) using anti-amyloid
strategies with disappointing results. It is clear that the “amyloid cascade hypothesis” alone …

Objective Inflammation plays a crucial role in the pathogenesis of mild cognitive impairment
(MCI) and Alzheimer's disease (AD). Our study aimed to analyse previous inconsistent …

Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely
overlooked. Astrocytes are integral to normal brain function and astrocyte reactivity is an …

Background: Inflammation is a part of the first line of defense of the body against invasive
pathogens, and plays a crucial role in tissue regeneration and repair. A proper inflammatory …

Introduction The biological pathways involved in the preclinical stage of the Alzheimer's
continuum are not well understood. Methods We used NeuroToolKit and Elecsys® …

Objective To measure CSF levels of biomarkers reflecting microglia and astrocytes
activation, neuroinflammation, and cerebrovascular changes and study their associations …